CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Arovella Therapeutics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Arovella Therapeutics Ltd
Osborne Park, U 12 L 1, 55 Howe St
Phone: +61 861425555p:+61 861425555 PERTH, VIC  3053  Australia Ticker: ALAALA

Business Summary
Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The Company's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The Company is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20236/30/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board ThomasDuthy 3/13/2023 3/13/2023
Chief Executive Officer, Managing Director, Director MichaelBaker 1/1/2022 1/2/2020
Chief Financial Officer, Company Secretary TimLuscombe 12/1/2023 12/1/2023
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
NovaDel Pharma, Inc. 1200 US Highway 22 Bridgewater NJ United States

Business Names
Business Name
ALA
Ampack Medical Pty Ltd
Eastland Medical Systems Ltd
5 additional Business Names available in full report.

General Information
Number of Employees: 14 (As of 6/30/2013)
Outstanding Shares: 909,628,062 (As of 12/31/2023)
Shareholders: 2,857
Stock Exchange: ASX
Fax Number: +61 894438858


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024